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The specificity of poliovirus encapsidation has been studied using a novel chimeric genome in which the gene encoding
firefly luciferase has been substituted for the VP2–VP3–VP1 genes of the poliovirus capsid (P1) gene. Transfection of RNA
transcribed in vitro from this genome resulted in a VP4-luciferase fusion protein which retained luciferase enzyme activity.
Since the detection of enzyme activity was dependent upon replication of the transfected RNA genome, we refer to these
genomes as replicons. The replicon encoding luciferase was encapsidated upon transfection of the genomic RNA into cells
previously infected with a recombinant vaccinia virus, VV-P1, which encodes the poliovirus type 1 capsid proteins (P1).
Infection of cells with each serial passage, followed by analysis of luciferase enzyme activity, revealed that encapsidated
replicons could be detected at the first passage with VV-P1. Amplification of the titer of encapsidated replicons occurred upon
serial passage with VV-P1, as evidenced by the high expression levels of luciferase enzyme activity following infection. Serial
passage of the luciferase replicons with poliovirus type 1, 2, or 3 resulted in the trans encapsidation into the type 1, 2, or 3
capsids, respectively. In contrast, serial passage with bovine enterovirus, Coxsackievirus A21 or B3, or enterovirus 70 did not
result in trans encapsidation, even though co-infection of cells with the replicon and different enteroviruses resulted in
high-level expression of luciferase. The results of this study highlight the specificity of poliovirus encapsidation and point to
the use of encapsidated replicons encoding luciferase as a reagent for dissecting elements of replication and encapsidation.
© 1998 Academic Press
INTRODUCTION
Picornaviruses are small, plus-strand RNA viruses
which include the enteroviruses (poliovirus, bovine en-
terovirus, Coxsackieviruses, and enterovirus 70), rhino-
viruses, cardioviruses, and apthoviruses (Koch and Koch,
1985). Picornavirus virions contain a single-stranded
RNA genome of approximately 7500 bp in length. Upon
infection of cells, the viral genome is translated into a
single polyprotein which is processed by virally encoded
proteases to generate the viral proteins (Kitamura et al.,
1981; Semler et al., 1981). This long single polyprotein is
functionally divided into three distinct regions: P1 en-
codes the capsid or structural proteins, while P2 and P3
encode the nonstructural or replication proteins. An ini-
tial cleavage of the polyprotein between the P1 and P2
regions is catalyzed by the 2A protease (2Apro) and oc-
curs cotranslationally at a tyrosine–glycine amino acid
pair (Nicklin et al., 1986, 1987; Toyoda et al., 1987). Sub-
sequent cleavages of the P2 and P3 region are catalyzed
by the protease 3Cpro at glutamine–glycine amino acid
pairs. Cleavage of the P1 protein occurs in trans by the
3CD protein, which is a fusion between 3Cpro and 3Dpol,
the viral polymerase (Kuhn and Wimmer, 1987; Harris et
al., 1990; Palmenberg, 1990).
The development of an infectious cDNA clone for po-
liovirus facilitated studies to delineate the role of viral
proteins and regions of the genome in replication (Kita-
mura et al., 1981; Racaniello and Baltimore, 1981). Early
studies from Kaplan and Racaniello demonstrated that
regions of the P1 gene could be deleted without com-
promising the capacity of the RNA to undergo self-repli-
cation (Kaplan and Racaniello, 1988). Follow-up studies
demonstrated that insertion of foreign genes into the P1
region resulted in expression as long as the translational
reading frame was maintained between the foreign gene
and the poliovirus P2 and P3 regions. Previous studies
from this laboratory have described the construction of
self-replicating genomes, termed replicons, which en-
code the nonstructural proteins of poliovirus down-
stream from a foreign gene substituted for the P1 region
(Porter et al., 1993, 1995, 1996, 1997; Ansardi et al., 1994;
Moldoveanu et al., 1995; Anderson et al., 1996a,b). The
transfection of the replicon RNA into cells resulted in
replication and expression of the gene substituted for the
P1 region.
Although the details of the mechanism and specificity
of poliovirus encapsidation are not known, early studies
identified poliovirus genomes which contained deletions
in the P1 gene that could be encapsidated if serially
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passaged in the presence of wild-type poliovirus (Cole et
al., 1971; Cole and Baltimore, 1973a,b,c; Cole, 1975).
These RNAs acted as defective interfering genomes (DI).
Further analysis of DI genomes revealed that the major-
ity of the deletions occurred in the VP2–VP3–VP1 genes
of the P1 region (Nomoto et al., 1975). Percy et al. (1992)
constructed a replicon which contained the gene encod-
ing chloramphenicol acetyltransferase (CAT) substituted
for VP4, VP2, and part of the VP3 genes. Transfection of
this RNA into cells followed by infection with wild-type
poliovirus resulted in the encapsidation of the replicon
encoding CAT. A detailed analysis of the encapsidation
of this replicon, though, was complicated by the pres-
ence of the wild-type helper virus in these preparations
which prevented the isolation and characterization of a
homogeneous population of encapsidated replicons. We
have demonstrated that transfection of replicon RNAs
into cells previously infected with a recombinant vaccinia
virus which expresses P1 (VV-P1) resulted in the encap-
sidation of the RNA by the P1 protein provided in trans.
Serial passage of the encapsidated replicon in the pres-
ence of VV-P1 resulted in the generation of stocks of the
encapsidated replicons.
Previous studies from this laboratory have described
the construction and characterization of encapsidated
replicons encoding foreign proteins. Although immuno-
precipitation was used to detect the encapsidated rep-
licons, this technique was not sensitive enough for
detailed analysis of poliovirus replication and encapsi-
dation. In the present study, we have generated encap-
sidated replicons which encode the firefly luciferase
marker protein. We demonstrate that infection of cells
with this replicon results in the production of enzymati-
cally active luciferase protein. The level of luciferase
detected from cells infected with the encapsidated rep-
licons correlated with the infectious dose. Co-infection of
cells with this replicon and other picornaviruses was
used to analyze replication, as well as to examine the
specificity of RNA encapsidation. The results of these
studies are discussed with respect to the use of this
novel replicon as a means of dissecting and character-
izing features of poliovirus replication and encapsida-
tion.
RESULTS
Construction of a replicon encoding luciferase
Previous studies from this laboratory have character-
ized the expression of foreign proteins from poliovirus-
based replicon genomes. In these studies, the complete
HIV-1 Pr55gag gene sequences were substituted for ei-
ther the entire P1 coding region or for the VP2, VP3, and
VP1 coding sequences (Porter et al., 1995). Upon serial
passage of in vitro transcribed RNA from each replicon
with VV-P1, a difference in the levels of encapsidated
RNA was detected. These results suggested that al-
though the VP4 capsid sequences are not required for
encapsidation, the presence of the VP4 gene sequences
might affect the efficiency of encapsidation. Based on
these results, we constructed replicons encoding the
luciferase gene substituted for the VP2–VP3–VP1 capsid
sequences, which maintains the VP4 capsid gene se-
quences positioned 59 to the luciferase gene sequences.
In order to subclone the luciferase gene, the poliovirus
cDNA pT7-IC was modified to contain a unique XhoI
restriction site between the VP4 and VP2 capsid genes
(Fig. 1A). Since poliovirus is translated as a single
polyprotein which is subsequently processed to gener-
ate mature proteins, a unique SnaBI restriction site was
introduced at nucleotide 3359, followed by coding se-
FIG. 1. Diagram of the replicon genome which contains the firefly luciferase gene. (A) Depiction of plasmid pT7-IC, which contains the complete
poliovirus infectious cDNA clone with specific restriction sites indicated. This plasmid contains the T7 RNA polymerase promoter with a unique SalI
restriction site for linearization of DNA before in vitro transcription of RNA. (B) Construction of pT7-IC-Luc. The complete gene encoding firefly
luciferase (nucleotides 105–1754) was amplified by PCR and cloned between unique XhoI and SnaBI restriction sites in the modified poliovirus cDNA.
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quences for 8 amino acids constituting a cleavage site
for the 2A protease: Thr-Lys-Asp-Leu-Thr-Thr-Tyr-Gly
(cleavage site underlined). To construct the replicon pT7-
Luc, PCR was used to amplify a 1.7-kb gene encoding
luciferase (nucleotides 105–1754) which was then sub-
cloned into the modified poliovirus cDNA between
unique XhoI and SnaBI restriction sites (Fig. 1B).
To determine that RNA from the replicon genomes
encoding luciferase would replicate in transfected cells,
RNA was transcribed in vitro from pT7-IC-Luc, as previ-
ously described (Porter et al., 1995). The RNA was then
transfected into cells which had been previously infected
for 2 h with VV-P1 at an m.o.i. of 10. After 6 h, the
infected/transfected cells were metabolically labeled,
and radiolabeled proteins were immunoprecipitated us-
ing anti-3Dpol antibodies. Examination of protein expres-
sion resulted in the detection of the poliovirus 3CD pro-
tein (data not shown). We have shown previously that
detection of 3CD by metabolic radiolabeling is indicative
of RNA replication (Porter et al., 1995). High levels of
luciferase enzyme activity were also detected from the
transfected cells (data not shown).
Encapsidation of the replicon encoding luciferase
In previous studies, we have demonstrated that RNA
from poliovirus-based replicon genomes could be en-
capsidated if transfected into cells previously infected
with a recombinant vaccinia virus, VV-P1, which ex-
presses the P1 protein (Ansardi et al., 1994; Porter et al.,
1993, 1995, 1996, 1997). Serial passage of encapsidated
replicons in VV-P1-infected cells resulted in the genera-
tion of stocks of the encapsidated replicon. In order to
generate a stock of encapsidated replicons encoding
luciferase (referred to as vIC-Luc), RNA transcribed in
vitro was transfected into cells infected with VV-P1; the
replicon was subsequently serially passaged in the pres-
ence of VV-P1. An aliquot of each passage was used to
infect HeLa H1 cells and the extracts were analyzed for
luciferase activity (Fig. 2). We found that the levels of
luciferase activity from the transfected cells (passage 0)
dropped (from 4,119,175 light units to approximately
231,450 light units) after one passage with VV-P1. By
passage 2, an increase in the luciferase levels was
detected from the infection of cells; by passages 3 and 4,
the levels of luciferase detected in cells infected with
encapsidated replicons had dramatically increased. We
have further passaged this stock of encapsidated repli-
con for approximately 50 serial passages to derive a
large scale stock suitable for further analysis.
Characterization of the encapsidated replicon
encoding luciferase
To examine protein expression from the vIC-Luc en-
capsidated replicons, cells were infected with titered
encapsidated replicon virus stock at an m.o.i. of 10 and
metabolically labeled at 6 h postinfection (Fig. 3A). Upon
incubation of the cell lysates with anti-3Dpol antibodies, a
72-kDa protein, which is consistent with the molecular
mass of the poliovirus 3CD protein, was detected (Fig.
3A, lane 2). Previous studies from this laboratory have
shown that upon immunoprecipitation of radiolabeled
proteins from poliovirus-infected cells with anti-3Dpol an-
tibody under similar labeling conditions, the 3CD protein
is predominantly detected (Porter et al., 1995). We next
wanted to characterize the luciferase protein expressed
from the replicon. After incubation of replicon-infected
cell lysates with anti-luciferase antibody, a protein with a
molecular mass of approximately 70 kDa was detected,
which is consistent with the size of the VP4-luciferase
fusion protein (Fig. 3A, lane 4). We did not detect lucif-
erase proteins of lower molecular mass, which might
indicate deletions of the luciferase gene within the rep-
licon after serial passage. Analysis of the replicon virion
RNA by reverse transcription PCR indicated that the
predominant DNA product amplified was the same size
as the initial VP4-luciferase gene (data not shown).
Since previous studies have suggested that the lucif-
erase enzyme is unstable in vivo (Andino et al., 1993), we
examined the stability of the luciferase fusion protein
expressed in replicon-infected cells by pulse-chase
analysis and immunoprecipitation using anti-luciferase
antibodies (Fig. 3B). For these studies, cells were in-
fected with vIC-Luc at an m.o.i. of 10 and pulse-labeled
for 30 min at 5 h postinfection. After pulse labeling,
FIG. 2. Comparison of the levels of encapsidation after RNA trans-
fection and serial passage with VV-P1. Cells infected with VV-P1 at an
m.o.i. of 10 were transfected with RNA transcribed in vitro from the
pT7-Luc replicon genome. Encapsidated replicons were harvested
from the transfected cells and a portion was analyzed for luciferase
activity as measured by light units (designated passage 0). The remain-
der was used for serial passages in cells which had been previously
infected with VV-P1 at an m.o.i. of 10 (passages 1–4). A portion of the
lysates from the each of the serial passages was used to infect cells for
the analysis of luciferase activity as described under Materials and
Methods.
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complete medium was added for 0.5-, 1-, and 2-h chase
periods. After the designated chase periods, infected
cells were processed as described for immunoprecipi-
tation with the anti-luciferase antibodies. A protein with a
molecular mass consistent with that of the VP4-lucif-
erase fusion protein (;70 kDa) was detected from in-
fected cells which were pulse-labeled. After incubation
of the pulse-labeled cells in complete medium, decreas-
ing amounts of the luciferase protein were detected as
the chase times increased from 0.5 to 2 h (Fig. 3B, lanes
2–5); the amount of the luciferase fusion protein did
decrease over time but was still detectable even after the
2-h chase period.
We next characterized the kinetics of protein expres-
sion from cells infected with the replicons encoding
luciferase. For this experiment, equivalent amounts of
cells were infected with vIC-Luc replicons at an m.o.i. of
10. Cells were also infected with another replicon, vIC-
Gag, which served as a negative control (Porter et al.,
1993). Infected cells were then harvested for standard
luciferase enzyme assays as described under Materials
and Methods at the time points indicated (Fig. 4A). Lu-
ciferase activity was first detected at 4 h postinfection
(measured in light units) from cells infected with vIC-Luc.
The amount of detectable light units increased steadily
and peaked at 12 h postinfection. Between 12 and 24 h
postinfection, the number of light units detected from the
cells infected with vIC-Luc declined steadily, which is
probably a result of increasing cytopathic effects on the
cells from the replicon infection. To determine if the
enzymatic activity detected from lysates from cells in-
fected with vIC-Luc replicons correlated with luciferase
fusion protein expression, equivalent numbers of cells
were infected at an m.o.i. of 10, metabolically labeled,
and harvested for immunoprecipitation with anti-lucif-
erase antibodies at various time points postinfection
(Fig. 4B). Consistent with the results from Fig. 4A, the
luciferase fusion protein was first detected at 4 h postin-
fection (lane 3). The levels of luciferase fusion protein
continued to increase until a maximum level was de-
tected at 6 to 8 h postinfection (Fig. 4B, lanes 4 and 5).
These results are in contrast with the results in Fig. 4A,
which shows the peak levels of luciferase enzyme activ-
ity at 12 h postinfection. These differences might be a
result of a limitation of the anti-luciferase antibody react
with all of the luciferase present in the samples. In other
words, the immunoprecipitations were not quantitative,
especially when the cell lysates contained large
amounts of the VP4-luciferase present at later times
postinfection.
To further characterize the encapsidated replicons
which encode luciferase, we analyzed the correlation
between the input virus and the measured light units
following a defined time postinfection. Using a known
quantity of the encapsidated replicon which encodes
luciferase, we determined the relationship between the
amount of virus (infectious units) and the measured light
units following infection (Fig. 5). We found a linear rela-
tionship between the input infectious units of replicons
and the measured light units from cells infected with 0.01
to 1 infectious unit per cell (see inset graph). The limit of
the level of sensitivity was at approximately 0.01 i.u. per
cell.
trans encapsidation of replicons encoding luciferase
In a previous study, we have found that the replicon
encoding HIV-1 gag could be trans-encapsidated when
serially passaged with poliovirus type 1 (Porter et al., 1993).
To demonstrate the presence of the replicon within the
FIG. 3. Analysis of protein expression from cells infected with replicons which encode luciferase. (A) Cells were infected at an m.o.i. of 10 with
vIC-Luc encapsidated replicons and metabolically labeled with Tran35S-label. Cell lysates were immunoprecipitated with the indicated antibodies. The
immunoprecipitates were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis followed by fluorography/autoradiography. Lanes
1 and 3, mock-infected cells; lanes 2 and 4, cells infected with vIC-Luc replicons. (B) Cells infected with vIC-Luc replicons were pulse-labeled for 30
min, followed by the addition of complete media for 0.5-, 1-, and 2-h chase periods. Cell lysates were incubated with anti-luciferase antibodies and
the immunoreactive proteins were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis followed by fluorography/autoradiography.
Lane 1, mock-infected cells; lanes 1–5, cells infected with vIC-Luc replicons. Molecular mass standards (MW) and positions of relevant proteins are
indicated; kDa, kilodalton; ab, antibody.
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stocks of poliovirus, we immunoprecipitated proteins from
co-infected cells with antibody specific for the HIV-1 gag
protein. However, detection of the replicon genome in the
presence of the wild-type genome was complicated due to
competition for radiolabel by both the replicon and wild-
type RNAs resulting in a loss of sensitivity.
The use of the replicon encoding luciferase allows for
a more sensitive assessment of replication in cells co-
infected with different picornaviruses. For these studies,
cells were co-infected with equivalent numbers of repli-
cons encoding luciferase and poliovirus types 1, 2, or 3
(Sabin strains) (Fig. 6A) or related picornaviruses, bovine
enterovirus, Coxsackievirus A21, Coxsackievirus B3, and
enterovirus 70 (Fig. 6B). The replication of the replicon
was monitored by determination of luciferase activity 6 h
after infection. From the examination of light units, we
determined that the levels of luciferase activity in cells
co-infected with vIC-Luc and type 1 poliovirus (Fig. 6A) or
Coxsackievirus B3 (Fig. 6B) were reduced by approxi-
mately 30–50% from that of cells infected with replicons
alone. In contrast, the expression of luciferase from the
replicon in the presence of poliovirus types 2 and 3,
bovine enterovirus, and Coxsackievirus A21 was en-
hanced at least 2-fold. Surprisingly, the level of luciferase
activity in cells co-infected with replicons and enterovi-
rus 70 was increased by approximately 10-fold over that
of cells infected with replicon alone.
To determine whether the replicon could be encap-
sidated into virions following serial passage in the
presence of a designated picornavirus, the replicons
were co-infected with the viruses at equivalent moi
(Fig. 7). Following complete cell lysis, the lysate was
harvested and used to reinfect cells. The next day, the
infected cells were harvested; the cell lysate was
designated as passage 1 (P1). This procedure was
repeated for an additional serial passage to generate
passage 2 (P2). Material from P1 and P2 was then
used to infect cells which were assayed for luciferase
activity. Passage of the replicon alone resulted in an
approximate 30-fold drop in luciferase activity after the
first passage (P1); by passage 2, the levels of lucif-
erase activity from vIC-Luc replicons alone were
barely detectable (approximately 100 light units (Figs.
7A and 7B)). This result is consistent with the fact that
FIG. 5. Correlation between initial virus multiplicity of infection and
luciferase activity from cells infected with vIC-Luc. Equivalent amounts
of cells were infected with 0.01, 0.1, 1, and 10 infectious units (i.u.) per
cell of vIC-Luc replicons. At 6 h postinfection, the cells were harvested
for luciferase assays as described under Materials and Methods.
(Inset) Expanded graph depicting the input infectious units of replicons
and luciferase activity from infections with 0.01 to 1.0 i.u. per cell; the
level of detection was approximately 0.01 i.u. per cell.
FIG. 4. Determination of luciferase enzyme activity from cells in-
fected with encapsidated replicons. (A) Cells were infected with vIC-
Luc replicons or Gag replicons (negative control) at an m.o.i. of 10. At
the time points indicated (hours postinfection), the infected cells were
harvested and analyzed for luciferase enzyme activity as described
under Materials and Methods. (B) Cells were infected with vIC-Luc and
metabolically labeled with Tran35S-label. At specific time points, cell
lysates were immunoprecipitated with anti-luciferase antibodies. Im-
munoreactive proteins were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis followed by fluorography/autora-
diography. Lane 1, mock-infected cells; lanes 2–7, cells infected with
vIC-Luc and harvested at 2, 4, 6, 8, 12, and 24 h postinfection. Molecular
mass standards (MW) are indicated and luciferase fusion proteins are
specified by arrowheads; kDa, kilodalton.
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the replicons do not encode their own capsid proteins
and therefore undergo only one round of infection.
Upon co-infection of cells with vIC-Luc and poliovirus
types 1, 2, or 3, luciferase activity was detected from each
serial passage (Fig. 7A). We observed a reduction of
about 50% in the levels of luciferase activity from P1 to
P2; the levels of activity though were still significantly
higher than background levels, demonstrating that the
replicons were trans-encapsidated upon passage with
types 1 and 2 poliovirus. In contrast, the vIC-Luc pas-
saged in the presence of poliovirus type 3 remained at
high levels for each serial passage. Although the lucif-
erase replicons are capable of competing with all three
serotypes of poliovirus for capsid proteins, the replicons
then appear to compete more efficiently for type 3 polio-
virus capsids.
To determine if trans encapsidation of the poliovirus
replicons would occur upon serial passage with different
picornaviruses, we passaged vIC-Luc in the presence of
Coxsackie A21 or B3 viruses, enterovirus 70, or bovine
enterovirus (Fig. 7B). After P2 of the replicons with the
different enteroviruses, the luciferase activity was below
the levels detected from the passage of replicons alone.
These results demonstrate that although the replicons
can replicate and express luciferase in cells co-infected
with the different picornaviruses, a mechanism exists
which excludes the replicons from trans encapsidation
with the different picornaviruses.
DISCUSSION
In this report, we have described the construction and
characterization of a replicon which encodes firefly lucif-
erase protein. Transfection of cells with the replicon
resulted in the expression of enzymatically active lucif-
erase. The replicons were encapsidated in poliovirions
FIG. 6. Replication of the replicon encoding luciferase in cells co-infected with other picornaviruses. Cells were co-infected with vIC-Luc replicons
and poliovirus type 1, 2, or 3 (A), or bovine enterovirus, enterovirus 70, Coxsackievirus A21, or Coxsackievirus B3 (B) at an equivalent m.o.i. of 10 for
both the replicons and the different picornaviruses. At 6 h postinfection, the co-infected cells were processed for luciferase enzyme activity as
described under Materials and Methods.
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by cotransfecting into cells previously infected with VV-
P1. Serial passage in the presence of VV-P1 resulted in
the generation of stocks of the encapsidated replicon.
Expression of luciferase protein correlated with the initial
starting amount of the encapsidated luciferase replicon.
The expression of luciferase from the replicon was de-
creased by co-infection of cells with type 1 poliovirus and
Coxsackievirus B3; luciferase expression was increased
in the presence of types 2 and 3 poliovirus, Coxsackievi-
rus A21, bovine enterovirus, and enterovirus 70. The
luciferase replicon could be encapsidated into poliovirus
type 1, 2, and 3 virions, but not trans encapsidated into
Coxsackieviruses A21 or B3, enterovirus 70, or bovine
enterovirus.
The availability of an encapsidated replicon which ex-
presses enzymatically active luciferase provides an impor-
tant experimental tool for dissecting elements of poliovirus
RNA replication and encapsidation. Previous studies have
reported on the construction of poliovirus replicons which
encode luciferase (Andino et al., 1993). Consistent with our
results, upon transfection into cells, the luciferase protein
expressed from the replicon was enzymatically active and
the levels correlated with replication of the genome. One
difference between this study and the present study was
FIG. 7. trans encapsidation of replicon genomes encoding luciferase upon passage in cells co-infected with other picornaviruses. Cells were co-infected
with vIC-Luc replicons and poliovirus type 1, 2, or 3 (A) or bovine enterovirus, enterovirus 70, Coxsackievirus A21, and Coxsackievirus B3 (B) at an equivalent
m.o.i. of 10. The replicons were passaged with the wild-type picornaviruses for two successive passages. Cells were infected with material from each
passage and processed for luciferase enzyme activity as described under Materials and Methods; P1, passage 1; P2, passage 2.
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that the luciferase protein was expressed as a fusion pro-
tein with the poliovirus VP4 protein. Interestingly, the ex-
pression of luciferase as a fusion protein did not drastically
affect the enzymatic activity of the protein. To our knowl-
edge, the expression of enzymatically active firefly lucif-
erase as a fusion protein has not been reported. Previous
studies using a replicon encoding luciferase protein which
was not a fusion protein with the VP4 capsid sequences
indicated that this enzyme was unstable in cells (Andino et
al., 1993). The results of our pulse–chase experiment,
though, demonstrate that the enzyme is stable for at least
2 h (and possibly longer). It is possible that the VP4 protein
stabilizes or protects the luciferase enzyme from degrada-
tion in the replicon-infected cells. Alternatively, since the
VP4 protein retains the signal for myristylation, this could
target the VP4-luciferase fusion protein to a different intra-
cellular compartment than luciferase expressed without the
VP4 protein. Additional studies using this replicon will be
needed to resolve these possibilities.
Our study is unique since this is the first demonstra-
tion that replicons encoding luciferase protein can be
encapsidated and, through serial passage with VV-P1,
grown in quantities sufficient for studies of RNA replica-
tion and encapsidation. Indeed, we have passaged the
encapsidated replicons described in the present study
for over 50 serial passages in the presence of VV-P1 and
found no deletion of the luciferase gene. Infection of cells
with this replicon results in the synthesis of enzymati-
cally active luciferase which can be detected from an
infection initiated with as few as 0.01 i.u. in our culture
system. Using the encapsidated replicons, we have de-
termined that the kinetics of luciferase expression, as
measured by an enzyme activity assay, parallels the
infectious life cycle of poliovirus. These results extend
our previous reports on the construction and character-
ization of replicons encoding foreign genes which relied
on immunoprecipitation of the foreign protein using spe-
cific antibodies.
We have used the luciferase enzyme assay to charac-
terize the trans encapsidation of the replicon in the
presence of VV-P1. We found that the amount of encap-
sidated replicon RNA in the first passage after the initial
transfection in the presence of VV-P1 was extremely low.
However, after 4 serial passages, the levels of luciferase
activity (and thus the amounts of encapsidated replicon)
had increased to significant levels, which were compa-
rable to those obtained from cells transfected with rep-
licon RNA. Since the cells are infected with VV-P1 at a
multiplicity of infection such that every cell is infected,
the results of these studies suggest that the transfected
replicon RNA, although competent for replication, does
not interact with the encapsidation machinery as effi-
ciently as RNA from the infection of cells with the encap-
sidated replicon. This could be due to subtle changes in
the replicon RNA during replication such that only a
subpopulation of the transfected RNA is competent for
encapsidation. Therefore, the generation of encapsi-
dated stocks of the replicon might then represent a
selection of replicon RNAs which are efficiently encap-
sidated. Alternatively, it is possible that transfected RNA
is localized to a different cellular compartment than the
RNA which enters the cell via infection. While this differ-
ence does not affect RNA replication, it could influence
subsequent encapsidation.
Early studies aimed at delineating the complexities of
poliovirus RNA encapsidation have described the use of
poliovirus DI genomes for investigating the specificity of
encapsidation (Kajigaya et al., 1985). In these studies, it
was shown that DI genomes of poliovirus could be trans-
encapsidated upon passage with poliovirus types 1, 2,
and 3, but not with Coxsackievirus B1. Percy et al. (1992)
have previously described chimeric poliovirus genomes
containing the CAT gene which were encapsidated upon
transfection into wild-type poliovirus-infected cells. How-
ever, the drawback to this approach for analysis of en-
capsidation is that the amount of RNA encoding CAT in
the mixed virus stocks is dependent not only upon the
efficiency of the transfection but also on the capacity of
the CAT RNA to amplify in the presence of wild-type
virus. In contrast, encapsidated replicons encoding lucif-
erase allow for a more direct evaluation of RNA encap-
sidation by the poliovirus P1 capsid protein. In the
present study, we found that the replicon encoding lucif-
erase could be detected in each of the serial passages
with poliovirus types 1, 2, or 3. We detected the highest
levels of luciferase enzyme activity from the replicons
passaged with type 3 poliovirus. The expression of lucif-
erase from replicons in cells infected with either polio-
virus type 1 or type 2 was lower than that in the presence
of type 3 poliovirus, although still significantly above
background. We do not think these differences are due to
interference with the replication of the replicon RNA in
the co-infected cells. In fact, luciferase expression was
enhanced in cells co-infected with replicon and either
type 2 or type 3 poliovirus. Our results, then, suggest that
the replicons compete more efficiently for type 3 capsids
than for type 1 or 2 capsids. If this is true, we would
predict that a recombinant vaccinia virus encoding type
3 poliovirus capsid proteins should allow for higher en-
capsidation efficiency than a virus encoding type 1 po-
liovirus capsids. Experiments are ongoing to test this
possibility.
Previous studies have suggested the possibility of
trans encapsidation of poliovirus genomes into other
picornavirus virions (Trautman and Sutmoller, 1971). If
this had occurred, it might have important consequences
for the pathogenesis of poliovirus, as well as for picor-
naviruses in general. For example, immunization of in-
fants that have a concurrent infection with another picor-
navirus (e.g., Coxsackie virus) with the poliovirus vaccine
might result in trans encapsidation of the poliovirus ge-
nome into a Coxsackie virion which would not be neu-
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tralized by anti-poliovirus antibodies. Using the replicon
genomes encoding luciferase, we examined the speci-
ficity of replicon RNA encapsidation upon passage with
several different enteroviruses. We found that co-infec-
tion of cells with the luciferase replicon and Coxsack-
ievirus A21 or enterovirus 70 resulted in an enhancement
of luciferase activity. Even so, it was clear from analysis
of the passage of the replicons with the different picor-
naviruses that trans encapsidation of the replicon RNA
did not occur. Thus, although a common encapsidation
signal exists between the three serotypes of poliovirus, it
is distinct from that for Coxsackievirus A21 and B3, en-
terovirus 70, and bovine enterovirus. Although the spe-
cific encapsidation signal for poliovirus is at present
unknown, one candidate which could be involved in
encapsidation is the 59 genome-linked protein VPg. In
support of this possibility, a previous study has identified
mutations within the VPg coding region that resulted in
RNA which replicated but did not produce infectious
virus, suggesting that genomes with mutant VPg proteins
were incapable of being encapsidated (Reuer et al.,
1990). Although VPg is covalently linked to both plus- and
minus-strand RNA, previous studies have demonstrated
that poliovirus RNA encapsidation is highly specific for
plus-strand RNA, suggesting that encapsidation is also
dependent upon signals specific for positive-sense RNA
(Novak and Kirkegaard, 1991). Thus, the encapsidation
signal for poliovirus RNA is most likely a complex con-
sisting of both RNA and protein determinants. The de-
velopment of an encapsidated replicon encoding lucif-
erase, as described in this study, provides an important
experimental tool with which to now dissect the com-
plexities of poliovirus RNA encapsidation.
MATERIALS AND METHODS
Tissue culture medium was purchased from Gibco/
BRL Company. The Tran35S-label (methionine and cys-
teine) and methionine- and cysteine-free Dulbecco’s
modified Eagle’s medium (DMEM) were purchased from
ICN Biochemicals. Synthetic DNA primers were pur-
chased from Gibco/BRL. The luciferase assay kit was
purchased from Promega.
Tissue culture cells and viruses
Cell monolayers of HeLa T4, BSC-40, or HeLa H1 cells
(obtained from ATCC) were grown in DMEM supple-
mented with 10% fetal bovine serum (Porter et al., 1995,
1996). The recombinant vaccinia virus, VV-P1, which ex-
presses the P1 capsid precursor protein in infected cells
has been previously described (Ansardi et al., 1991; Mor-
row et al., 1994, 1995, 1996a,b). Poliovirus types 1, 2, and
3 (Sabin strains) were obtained from Wyeth-Lederle, Vac-
cines. Coxsackie B3, Coxsackie A21, enterovirus 70, and
bovine enterovirus were obtained from ATCC; viruses
were grown and titered in HeLa H1 cells.
Construction of replicons containing the luciferase
gene
To generate the replicons containing the luciferase
gene, a modified version of the poliovirus cDNA, pT7-
IC, was used (Porter et al., 1995). The replicon ge-
nome, pT7-ENV (825 aa)/VP4, contains the HIV-1 en-
velope gene substituted for the poliovirus VP2, VP3,
and VP1 capsid genes (Anderson et al., 1996a,b). This
genome contains a unique XhoI restriction site at
nucleotide 949, preceded by the VP4 capsid gene. The
genome also contains a unique SnaBI restriction site
at the 39 end of the P1 region at nucleotide 3359,
followed by 8 amino acids encoding a cleavage site for
the 2A protease (cleavage site underlined): Thr-Lys-
Asp-Leu-Thr-Thr-Tyr-Gly.
To generate the replicon cDNA pT7-Luc, the luciferase
gene (nucleotides 105–1754) was amplified from the
plasmid pGEM-luc (Promega) using the following prim-
ers: 59-CTC-GAG-GAA-GAC-GCC-AAA-AAC-ATA-AAG-39
and 59-GTT-AAC-CAA-TTT-GGA-CTT-TCC-GCC-39. The
amplified DNA fragment contains a unique XhoI site at
the 59 end and a HpaI site at the 39 end. The fragment
was digested with XhoI and HpaI and ligated into the
plasmid pT7-ENV (825 aa)/VP4 after digestion of the
plasmid with XhoI and SnaBI. The resulting plasmid pT7-
Luc, contains the complete gene encoding firefly lucif-
erase positioned between nucleotides 949 and 3359,
substituted in-frame for the VP2, VP3, and VP1 capsid
genes of poliovirus.
Encapsidation of replicons
Previous studies from this laboratory have described
the encapsidation and serial passage of replicon ge-
nomes containing foreign gene sequences using the
recombinant vaccinia virus VV-P1 to provide P1 in trans
(Porter et al., 1993, 1995, 1996, 1997). To encapsidate the
replicon RNA, HeLa T4 cells were infected with 5 PFU/
cell of VV-P1, which expresses the poliovirus capsid
precursor protein P1 (Ansardi et al., 1991). At 2 h postin-
fection, the cells were then transfected with RNA tran-
scribed in vitro from the pT7-Luc replicon genome (Porter
et al., 1995). The cultures were harvested and encapsi-
dated replicons were collected by ultracentrifugation
(Porter et al., 1995).
To generate virus stocks of encapsidated replicons
encoding the luciferase protein, HeLa H1 cells were
infected with 10–20 PFU/cell of VV-P1 for 2 h. The cells
were then infected with lysate from the VV-P1-infected
cells transfected with replicon RNA. The cells were har-
vested at 24 h postinfection and the supernatants, des-
ignated pass 1 (P1), were then stored at 270°C or used
immediately for additional serial passages in the pres-
ence of VV-P1 (Porter et al., 1995).
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Metabolic labeling and immunoprecipitation of viral
proteins
In order to metabolically label proteins from infected/
transfected cells, the cultures were starved for methio-
nine/cysteine, at the times indicated, by incubation in
DMEM minus methionine/cysteine followed by the addi-
tion of Tran35S-label. For pulse–chase analysis, complete
medium was added to infected cells after labeling with
Tran35S-label, and infections were harvested at the indi-
cated time points. Infected cells were processed for
radioimmunoprecipitation as previously described and
incubated with the appropriate antibodies (Porter et al.,
1995). The immunoprecipitates were collected after the
addition of protein A–Sepharose and analyzed by SDS–
polyacrylamide gel electrophoresis as previously de-
scribed (Porter et al., 1995).
Estimation of virus titers of encapsidated replicon
virus stocks
Encapsidated replicons do not encode their own cap-
sid proteins and thus cannot form plaques on cell mono-
layers. To determine the virus titers of encapsidated
replicons encoding luciferase, cells were infected with
serial dilutions of the encapsidated replicon virus stocks;
similar amounts of cells were infected with specific
amounts of type 1 Mahoney poliovirus (as determined by
plaque assay). At 5 h postinfection, cells were metabol-
ically labeled, and specific viral proteins were immuno-
precipitated with anti-3Dpol antibodies. After separation
of proteins by SDS–PAGE, the gels were subjected to
phosphorimagery to quantitate the radioactivity in each
sample. A standard curve was generated from the quan-
titation of protein expressed from known amounts
(plaque-forming units) of type 1 Mahoney poliovirus. The
values obtained from the quantitation of protein ex-
pressed from the luciferase replicons were then plotted
on the poliovirus standard curve to estimate the titer. In
previous studies, we have shown that the titer of the
encapsidated replicon virus stocks, referred to as infec-
tious units (i.u.), correlated with plaque-forming units
from wild-type poliovirus (Ansardi et al., 1994; Morrow et
al., 1994, 1996a,b).
Luciferase assays
For luciferase assays, equivalent amounts of cells were
infected with titered virus stocks of encapsidated replicons
with designated moi. At 5–7 h postinfection, the culture
medium was removed, and the infected cells were washed
23 with PBS (phosphate-buffered saline). The cells were
then scraped from the tissue culture dishes, resuspended
in 1 ml PBS, and pelleted at 14,000g for 2 min at room
temperature. After discarding the supernatant, the cell pel-
lets were used for assays immediately or stored at 270°C.
For assays, the cell pellets were resuspended in 100 ml 13
lysis buffer [25 mM Tris–phosphate, pH 7.8, 2 mM DTT
(dithiothreitol), 2 mM DCTA (1, 2 diaminocyclohexane-
N,N,N9,N9-tetraacetic acid), 10% glycerol, and 1% Triton
X-100] and incubated at room temperature for 10 min. In a
separate tube, 10 ml of the room-temperature cell lysate
was mixed with 100 ml of the luciferase assay reagent (20
mM tricine, 1.07 mM (MgCO3)4 Mg(OH)2 z 5 H2O, 2.67 mM
MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 mM coenzyme A,
470 mM luciferin, 530 mM ATP, pH 7.8), and 50 ml of the
mixture was assayed for light detection using a luminom-
eter (Monolight 2010, Analytical Luminescence Laborato-
ries). The data are presented as relative light units.
Co-infection of cells with replicons and other
picornaviruses
Cells were co-infected with the encapsidated repli-
cons encoding luciferase and designated picornaviruses
at an equivalent m.o.i. of 10. Viruses were allowed to
adsorb for 1 h at 37°C. The inoculum was then removed
and replaced with complete medium. The infection was
allowed to proceed for 6 h, at which time cells were
processed for luciferase assays. For the encapsidation
experiments, the co-infected cultures were incubated for
24 h, at which time a complete cytopathic effect had
occurred. Following three freeze–thaw cycles and re-
moval of cell debris, one-half of the supernatant was
used to reinfect cells; the other half was stored at
270°C. After a 1-h adsorption, the inoculum was re-
moved and the infection continued for an additional 24 h.
The cultures were processed as before and repassaged
on cells for a total of two passages. After two serial
passages, cells were infected for 6 h with material from
each passage and processed for luciferase assays.
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